CIK 0001962918
SLRN ACELYRIN, Inc.
Insider trading from SEC Form 4. Last filing May 23, 2025.
In brief
ACELYRIN, Inc. (SLRN) has 27 SEC Form 4 filings on file from 13 insiders, the latest filed on May 23, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
5 open-market trades have been scored at SLRN. The newest: Shephard Mpofu (Chief Medical Officer) sold $8,811 of stock on Mar 17, 2025, filed Mar 19, 2025, scored 30 (weak). The largest of the 5 shown: Shao-Lee Lin (Chief Executive Officer) sold $119k on Feb 20, 2024, scored 35 (weak). 3 insiders sold within 14 days of each other around Mar 17, 2025.
2 Form 144 notices of planned sales are on file, the latest filed Mar 14, 2025.
Last 90 days
Signals
Open-market buys and sells at ACELYRIN, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Shephard Mpofu Chief Medical Officer sell | $8,811 3,211 shares | -3% | - | |
| 30Weak | Amar Murugan Chief Legal Officer sell | $11k 3,913 shares | -3% | - | |
| 47Moderate | Mina Kim Chief Executive Officer sell | $49k 17,986 shares | -3% | - | |
| 35Weak | Shao-Lee Lin Chief Executive Officer sell | $119k 15,701 shares | -1% | - | |
| 34Weak | Shao-Lee Lin Chief Executive Officer sell | $79k 10,691 shares | -1% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 14, 2025 | Kim Mina Officer, Director | 18,052 0.02% of outstanding | $50k | Mar 17, 2025 | none |
| Mar 20, 2024 | Peloso Paul Former Affiliate | 56,129 0.06% of outstanding | $470k | Mar 20, 2024 | none |
Transactions
The newest 50 of 57 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2025 | Henry O Gosebruch director | DDisposition to issuer Common Stock | -50,000 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Mina Kim Chief Executive Officer | AGrant or award Common Stock | +89,526 | - | - | 770,833 | May 23, 2025 |
| May 21, 2025 | Bruce C Cozadd director | DDisposition to issuer Director Stock Option (right to buy)derivative | -183,434 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Beth C Seidenberg director | DDisposition to issuer Common Stock | -60,000 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | AyurMaya Capital Management Company, LP director, owner, other | DDisposition to issuer Common Stock, par value $0.00001 per share ("Common Stock")indirect: See footnotes | -9,334,735 | $0.00 | $0 | 0 | May 23, 2025 |
| May 21, 2025 | Amar Murugan Chief Legal Officer | DDisposition to issuer Common Stock | -121,587 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Lynn A. Tetrault director | DDisposition to issuer Director Stock Option (right to buy)derivative | -43,680 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Shephard Mpofu Chief Medical Officer | DDisposition to issuer Common Stock | -121,789 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Daniel J. Becker director | DDisposition to issuer Common Stock | -2,999 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | DDisposition to issuer Common Stockindirect: See footnote | -14,675 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Dawn Svoronos director | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Mina Kim Chief Executive Officer | DDisposition to issuer Common Stock | -770,833 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Henry O Gosebruch director | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Dawn Svoronos director | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Lynn A. Tetrault director | DDisposition to issuer Director Stock Option (right to buy)derivative | -89,955 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Shephard Mpofu Chief Medical Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -328,860 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Daniel J. Becker director | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Beth C Seidenberg director | DDisposition to issuer Common Stockindirect: See footnote | -9,790,729 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Amar Murugan Chief Legal Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -525,000 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Bruce C Cozadd director | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Bruce C Cozadd director | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Mina Kim Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -1,195,856 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Dawn Svoronos director | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Henry O Gosebruch director | DDisposition to issuer Director Stock Option (right to buy)derivative | -155,450 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Shephard Mpofu Chief Medical Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -142,586 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Daniel J. Becker director | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Beth C Seidenberg director | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Mina Kim Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -190,114 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Dawn Svoronos director | DDisposition to issuer Director Stock Option (right to buy)derivative | -155,450 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Shephard Mpofu Chief Medical Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -118,858 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Beth C Seidenberg director | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | DDisposition to issuer Director Stock Option (right to buy)derivative | -28,675 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Mina Kim Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -85,226 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | DDisposition to issuer Director Stock Option (right to buy)derivative | -86,206 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Patrick Machado director | DDisposition to issuer Director Stock Option (right to buy)derivative | -40,567 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | Mina Kim Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -362,719 | - | - | 0 | May 23, 2025 |
| May 15, 2025 | Mina Kim Chief Executive Officer | AGrant or award Common Stock | +30,851 | $0.00 | $0 | 702,604 | May 19, 2025 |
| May 15, 2025 | Mina Kim Chief Executive Officer | FTax withholding Common Stock | -11,039 | $2.17 | $24k | 691,565 | May 19, 2025 |
| May 15, 2025 | Mina Kim Chief Executive Officer | FTax withholding Common Stock | -10,258 | $2.17 | $22k | 681,307 | May 19, 2025 |
| Mar 17, 2025 | Shephard Mpofu Chief Medical Officer | SOpen-market sale Common Stock | -3,211 | $2.74 | $8,811 | 121,789 | Mar 19, 2025 |
| Mar 17, 2025 | Amar Murugan Chief Legal Officer | SOpen-market sale Common Stock | -3,913 | $2.74 | $11k | 121,587 | Mar 19, 2025 |
| Mar 17, 2025 | Mina Kim Chief Executive Officer | SOpen-market sale Common Stock | -17,986 | $2.74 | $49k | 671,753 | Mar 19, 2025 |
| Jan 23, 2025 | Amar Murugan Chief Legal Officer | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 125,500 | Jan 24, 2025 |
| Jan 23, 2025 | Mina Kim Chief Executive Officer | AGrant or award Common Stock | +575,000 | $0.00 | $0 | 689,739 | Jan 24, 2025 |
| Jan 23, 2025 | Shephard Mpofu Chief Medical Officer | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 125,000 | Jan 24, 2025 |
| Nov 25, 2024 | Amar Murugan Chief Legal Officer | AGrant or award Employee Stock Option (right to buy)derivative | +525,000 | $0.00 | $0 | 525,000 | Nov 27, 2024 |
| Feb 20, 2024 | Shao-Lee Lin Chief Executive Officer | SOpen-market sale Common Stock | -15,701 | $7.60 | $119k | 1,587,335 | Feb 22, 2024 |
| Jan 9, 2024 | Gil M Labrucherie Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +855,513 | $0.00 | $0 | 855,513 | Jan 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- AyurMaya Capital Management Company, LPdirector, owner, other
- Daniel J. Beckerdirector
- Bruce C Cozaddceo, chair, officer, director
- Henry O Gosebruchdirector
- Mina KimChief Legal & Admin. Officer
- Gil M LabrucherieChief Financial Officer
- Shao-Lee LinChief Executive Officer
- Patrick Machadodirector
- Shephard MpofuChief Medical Officer
- Amar MuruganChief Legal Officer
- Beth C Seidenbergdirector, owner
- Dawn Svoronosdirector
- Lynn A. Tetraultdirector
Questions about SLRN
Answered from the filings on this page, as of the latest one.
Are insiders buying SLRN?
No. In the last 90 days no insider at ACELYRIN, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SLRN on the open market?
Shephard Mpofu (Chief Medical Officer) sold $8,811 of SLRN on Mar 17, 2025 and filed the Form 4 on Mar 19, 2025. InsiderTell scored 30 (weak), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at ACELYRIN, Inc.?
13 people have filed a Form 4 at ACELYRIN, Inc., among them AyurMaya Capital Management Company, LP (director and 10% owner), Daniel J. Becker (director), Bruce C Cozadd (CEO, chair and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.